Publications by authors named "Richard Labotka"

Claim this Profile
F
Final OS analyses from the TOURMALINE- MM3 and -MM4 RCTs of ixazomib maintenance in newly diagnosed multiple myeloma.
Meletios A Dimopoulos, Sagar Lonial, Wee-Joo Chng, Shinsuke Iida, María-Victoria Mateos, Richard Labotka

Blood Cancer J· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modeling serum M-protein response for early detection of biochemical relapse in myeloma patients treated with bortezomib, lenalidomide and dexamethasone.
Yuki Otani, Yunqi Zhao, Guanyu Wang, Richard Labotka, Mark Rogge

CPT Pharmacometrics Syst Pharmacol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ixazomib plus daratumumab and dexamethasone: Final analysis of a phase 2 study among patients with relapsed/refractory multiple myeloma.
Sosana Delimpasi, Meletios A Dimopoulos, Jan Straub, Argiris Symeonidis, Luděk Pour, Richard Labotka

Am J Hematol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjusting for subsequent therapies in the TOURMALINE-MM1 study shows clinically meaningful improvement in overall survival with addition of ixazomib to lenalidomide and dexamethasone.
Karthik Ramasamy, Nizar J Bahlis, Shaji K Kumar, Arun Kumar, Holly Cranmer, Richard Labotka

Haematologica· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Late versus early response and depth of response are associated with improved outcomes in patients with newly diagnosed multiple myeloma enrolled in the TOURMALINE-MM2 trial.
Paul G Richardson, Thierry Facon, Christopher P Venner, Nizar J Bahlis, Fritz Offner, Richard Labotka

EJHaem· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ixazomib Versus Placebo as Postinduction Maintenance Therapy in Newly Diagnosed Multiple Myeloma Patients: An Analysis by Age and Frailty Status of the TOURMALINE-MM4 Study.
Sara Bringhen, Luděk Pour, Reuben Benjamin, Sebastian Grosicki, Chang-Ki Min, Richard J Labotka

Clin Lymphoma Myeloma Leuk· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose Titration of Ixazomib Maintenance Therapy in Transplant-Ineligible Multiple Myeloma: Exposure-Response Analysis of the TOURMALINE-MM4 Study.
Jaydeep K Srimani, Paul M Diderichsen, Michael J Hanley, Richard Labotka, Neeraj Gupta

Clin Pharmacol Ther· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quality of life and symptoms among patients with relapsed/refractory AL amyloidosis treated with ixazomib-dexamethasone versus physician's choice.
Vaishali Sanchorawala, Ashutosh D Wechalekar, Kihyun Kim, Stefan O Schönland, Heather J Landau, Richard Labotka

Am J Hematol· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MRD dynamics during maintenance for improved prognostication of 1280 patients with myeloma in the TOURMALINE-MM3 and -MM4 trials.
Bruno Paiva, Irene Manrique, Meletios A Dimopoulos, Francesca Gay, Chang-Ki Min, Richard Labotka

Blood· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A pooled analysis of outcomes according to cytogenetic abnormalities in patients receiving ixazomib- vs placebo-based therapy for multiple myeloma.
Wee-Joo Chng, Sagar Lonial, Gareth J Morgan, Shinsuke Iida, Philippe Moreau, Richard Labotka

Blood Cancer J· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of ixazomib-lenalidomide-dexamethasone therapy on overall survival in multiple myeloma patients: Analysis of the emerging-markets subgroup of the TOURMALINE-MM1 trial.
Andrew Spencer, Olga Samoilova, Wee-Joo Chng, Richard Labotka, Cong Li

EJHaem· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetic/pharmacodynamic joint modeling of ixazomib efficacy and safety using data from the pivotal phase III TOURMALINE-MM1 study in multiple myeloma patients.
Jaydeep K Srimani, Paul M Diderichsen, Michael J Hanley, Karthik Venkatakrishnan, Richard Labotka

CPT Pharmacometrics Syst Pharmacol· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trial.
Meletios A Dimopoulos, Fredrik Schjesvold, Vadim Doronin, Olga Vinogradova, Hang Quach, Richard Labotka

Blood Cancer J· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma.
Paul G Richardson, Shaji K Kumar, Tamás Masszi, Norbert Grzasko, Nizar J Bahlis, Richard Labotka

J Clin Oncol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma.
Martin Kaiser, Meral Beksaç, Nina Gulbrandsen, Fredrik Schjesvold, Roman Hájek, Richard Labotka

Ann Hematol· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial.
Meletios A Dimopoulos, Ivan Špička, Hang Quach, Albert Oriol, Roman Hájek, Richard Labotka

J Clin Oncol· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Deepening responses associated with improved progression-free survival with ixazomib versus placebo as posttransplant maintenance in multiple myeloma.
Hartmut Goldschmidt, Meletios A Dimopoulos, S Vincent Rajkumar, Katja C Weisel, Philippe Moreau, Richard Labotka

Leukemia· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma.
Martin Kaiser, Meral Beksaç, Nina Gulbrandsen, Fredrik Schjesvold, Roman Hájek, Richard Labotka

Ann Hematol· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma.
Meletios A Dimopoulos, Andrzej J Jakubowiak, Philip L McCarthy, Robert Z Orlowski, Michel Attal, Richard Labotka

Blood Cancer J· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ixazomib maintenance therapy in newly diagnosed multiple myeloma: An integrated analysis of four phase I/II studies.
Meletios A Dimopoulos, Jacob P Laubach, Maria Asunción Echeveste Gutierrez, Norbert Grzasko, Craig C Hofmeister, Richard Labotka

Eur J Haematol· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Pharmacology of Ixazomib: The First Oral Proteasome Inhibitor.
Neeraj Gupta, Michael J Hanley, Cindy Xia, Richard Labotka, R Donald Harvey

Clin Pharmacokinet· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 2 study of all-oral ixazomib, cyclophosphamide and low-dose dexamethasone for relapsed/refractory multiple myeloma.
Shaji K Kumar, Norbert Grzasko, Sosana Delimpasi, Wieslaw W Jedrzejczak, Sebastian Grosicki, Richard Labotka

Br J Haematol· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma.
Meletios A Dimopoulos, Sebastian Grosicki, Wiesław W Jędrzejczak, Hareth Nahi, Astrid Gruber, Richard Labotka

Eur J Cancer· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adoption of triplet therapy and clinical outcomes in routine practice among newly diagnosed multiple myeloma patients not receiving frontline stem cell transplant in the USA.
Parameswaran Hari, Marlo Blazer, Aditya Raju, Eileen Farrelly, Richard Labotka

Expert Rev Hematol· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial.
Meletios A Dimopoulos, Francesca Gay, Fredrik Schjesvold, Meral Beksac, Roman Hajek, Richard Labotka

Lancet· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis